For the Quarter Ending September 2025
North America
• In North America, the Monosulfiram Price Index rose by ~0.7% quarter-over-quarter, supported by drawn-down distributor inventories and steady end-use demand.
• The average Monosulfiram price for the quarter was approximately USD 16,100.00/MT (conservative estimate using regional quotes and import parity).
• Monosulfiram Spot Price remained firm as buyers replenished low stocks after seasonal consumption and select plant maintenance tightened prompt availability briefly.
• Monosulfiram Demand Outlook is constructive from veterinary, personal care and topical pharma sectors, underpinning steady procurement into Q4.
• Monosulfiram Production Cost Trend was stable with adequate feedstock supplies and normalised manufacturing runs following turnarounds.
• Monosulfiram Price Forecast suggests modest upward bias into Q4 as restocking and ongoing export obligations support near-term demand.
• Low downstream inventories in several distribution hubs tightened immediate availability, while regular shipments from producers maintained overall cadence.
• Reliable port throughput and inland trucking contained logistical risk, so price resilience primarily reflected inventory and demand balances.
Why did the price of Monosulfiram change in September 2025 in North America?
• Drawn-down inventories and seasonal monsoon-equivalent demand in end-use sectors prompted restocking, tightening prompt availability and supporting prices.
• Stable feedstock and manufacturing runs kept production-cost pressure limited, so price moves were driven by inventory/demand dynamics rather than input-cost spikes.
• Smooth logistics and steady freight conditions prevented landed-cost volatility, allowing regional supply-demand balances to set transactional pricing.
APAC
• In India, the Monosulfiram Price Index fell by 0.33% quarter-over-quarter, reflecting subdued downstream demand and procurement.
• The average Monosulfiram price for the quarter was approximately USD 16032.41/MT, reflecting Mumbai trading and production.
• Monosulfiram Spot Price remained firm in August due to restocking, limited inventories and steady demand.
• Monosulfiram Demand Outlook indicates sustained monsoon-driven requirements from veterinary, personal care and topical pharmaceutical applications.
• Monosulfiram Production Cost Trend remained stable as feedstock availability and manufacturing runs showed no disruptions.
• Monosulfiram Price Forecast reflects modest upward pressure into Q4 as downstream buyers replenish depleted inventories.
• Monosulfiram Price Index movements were primarily demand-led, with distributors reducing purchases and prioritizing consumption-driven procurement.
• Low downstream inventories and export obligations tightened near-term availability, supporting price resilience amid monsoon purchasing.
Why did the price of Monosulfiram change in September 2025 in APAC?
• Seasonal monsoon-driven demand in veterinary and personal care sectors increased final-quarter consumption, tightening immediate market availability.
• Downstream inventories were drawn down earlier, prompting restocking and contributing to upward price pressure in September.
• Production remained stable with no feedstock constraints, while handling charges and export obligations added cost support.
Europe
• In Europe, the Monosulfiram Price Index fell by ~0.5% quarter-over-quarter, reflecting generally subdued procurement but pockets of restocking.
• The average Monosulfiram price for the quarter was approximately USD 16,500.00/MT (conservative estimate based on limited regional transaction data and import parity).
• Monosulfiram Spot Price showed firmness in select markets where distributors replenished low stocks, while overall spot liquidity remained muted.
• Monosulfiram Demand Outlook indicates steady requirements from veterinary and topical formulations, with seasonal buying supporting measured purchases.
• Monosulfiram Production Cost Trend stayed stable, with feedstock availability adequate and energy costs only modestly variable.
• Monosulfiram Price Forecast points to modest firming into Q4 as replenishment by distributors and seasonal demand lift near-term enquiry.
• Low-to-moderate distributor inventories in some markets tightened prompt availability, while other markets bore carryover stocks—producing mixed regional Price Index signals.
• Efficient port handling and inland logistics preserved supply continuity, limiting abrupt price moves despite localized tightness.
Why did the price of Monosulfiram change in September 2025 in Europe?
• Seasonal and consumption-driven restocking in veterinary and personal care segments supported localized price firmness, while other markets with higher inventories kept broader pressure modest.
• Stable feedstock supply and steady production costs removed major upward cost drivers, so price moves were largely demand/inventory-led.
• Smooth logistics and predictable freight dynamics allowed procurement timing to determine transactional pricing rather than freight or disruption-related premiums.
For the Quarter Ending June 2025
Asia Pacific (APAC)
• Why did the price change in July 2025?
The Price Index for Monosulfiram in Asia dipped further in early July 2025 as distributors remained cautious due to existing inventory surpluses.
• In India June’s Monosulfiram Spot Price stood at USD 15,989.51 per metric ton and reflected a 0.72% decline.
• The Monosulfiram Spot Price in Asia had earlier increased in April and May 2025 that was driven by seasonal demand from pharmaceuticals and personal care segments. The prices began to decline in June due to demand fatigue and surplus stock conditions.
• The Monosulfiram Price Forecast turned bearish in June as buyers abstained from fresh procurement amidst tepid downstream off-take, compounded by monsoon-related lifestyle shifts that curtailed product usage.
• Throughout Q2, the Monosulfiram Production Cost Trend remained largely stable, as feedstock availability and operating rates at Indian manufacturing units continued uninterrupted.
• Despite initial bullish procurement behaviour in April, June saw visible demand weakening from key sectors like derma, personal hygiene, and animal care, softening the Monosulfiram Demand Outlook.
• Strategic stockpiling in April and May led to bloated inventories by June, which discouraged replenishment and pressured market sentiment downward.
• Efficient inland distribution persisted across India, even during monsoon progression, preventing any supply-side disruption or logistics-induced price volatility.
• Domestic manufacturers maintained regular production schedules, with supply discipline observed in May contributing to temporary price firmness.
• With Q2 ending on a subdued note, July opened with restrained spot purchases, as importers and end-users monitored inventory drawdowns and market corrections.
North America
• Why did the price change in July 2025?
The Monosulfiram Price Index in North America showed signs of softening in early July 2025 as consumer healthcare and veterinary distributors scaled back fresh procurement amid adequate inventories and moderate summer demand.
• The Monosulfiram Spot Price in April and May saw gradual firming as procurement accelerated for summer healthcare formulations, particularly for veterinary skin care and antifungal topical products.
• By June, downstream demand signals began to decelerate slightly, triggering conservative inventory planning, which reflected in a flat-to-weak Monosulfiram Price Forecast.
• Stable production and secure feedstock access kept the Monosulfiram Production Cost Trend neutral throughout the quarter in North America.
• Demand from dermatology and hygiene segments remained moderate, influenced by a less severe fungal outbreak season and greater consumer inventory optimization.
• No major import reliance or supply delays were reported; domestic formulators maintained scheduled procurement tied to monthly usage rates.
• Distributors reported higher-than-average stock availability in June, having procured aggressively during the early Q2 price incline phase.
• North American formulators strategically spaced out their purchase cycles post-May, leading to subdued market movement in June.
• The Q2 cycle concluded with a relatively balanced market, with early-quarter strength offset by end-quarter caution, ahead of a modest July slowdown in Monosulfiram Demand Outlook.
Europe
• Why did the price change in July 2025?
In Europe, the Price Index for Monosulfiram declined marginally in July 2025 due to sluggish consumption recovery and cautious stockholding following weak Q2 off-take in dermatological and veterinary product lines.
• The Monosulfiram Spot Price in Europe showed modest strength in April amid early seasonal demand, particularly from personal care manufacturers anticipating summer skincare product launches.
• May registered stable procurement from pharmaceutical manufacturers, but lacked significant momentum, with Monosulfiram Price Forecast signals remaining neutral.
• By June, demand contraction set in as downstream buyers, facing unexciting consumer movement, deferred procurement — a trend echoed in the broader Monosulfiram Demand Outlook.
• European buyers prioritized lean inventory models, especially in Western Europe, to avoid surplus accumulation observed during Q1 and early Q2.
• The Monosulfiram Production Cost Trend remained stable in Europe, with no supply-side inflation reported. Local manufacturing operated on demand-based planning.
• Regional distribution logistics functioned efficiently throughout Q2, with no external disruptions affecting availability or delivery cycles.
• Export-reliant buyers in Eastern Europe showed weaker activity in May and June due to soft purchasing cues from Middle East and African clients.
• Q2 closed with European Monosulfiram markets entering July cautiously, maintaining only operational inventories and trimming future spot purchases.
For the Quarter Ending March 2025
North America
The Monosulfiram market in North America experienced a stable and consistent phase during the first quarter of 2025. Market conditions remained steady throughout the period with prices holding firm and trading activity being well-managed across the region. During this quarter, certain tariff adjustments were introduced and affected various pharmaceutical ingredients based on their product type and category. However, the overall impact on Monosulfiram remained controlled with suppliers and buyers adjusting procurement strategies accordingly.
Many buyers focused on maintaining balanced inventory levels and preferred to avoid bulk purchases in anticipation of any possible market shifts. Demand from downstream pharmaceutical sectors in dermatology and anti-parasitic applications, continued at a moderate and predictable pace. Seasonal transition from winter to early spring brought no sharp demand spikes and allowed suppliers to manage supply chains smoothly without major disruptions.
The steady availability of cargo space and reliable logistics routes further supported market stability. As a result, Monosulfiram prices moved within a tight range and both buyers and suppliers kept a close watch on tariff policies and upcoming production cycles likely to shape the upcoming period activity.
Asia Pacific
The Monosulfiram market in Asia Pacific showed a quarterly price drop of 7.46% in first quarter of 2025. This decline was mainly driven by weak demand and well-managed inventories across the region. Pharmaceutical companies across key Asia Pacific markets displayed cautious procurement behaviour during this period. Festive holidays in major exporting countries led to temporary production slowdowns and delayed purchasing activity, which played a part in keeping prices stable across the region.
Seasonal transitions from winter to early spring also meant demand for certain dermatology medicines softened, lowering procurement volumes. Suppliers strategically adjusted prices to attract steady orders without allowing excess stock to build up. Buyers planned their purchases carefully and avoided any unnecessary inventory pileups. The region’s exporters also faced competitive market conditions, where steady pricing became essential to maintain trade flows.
Overall, the price correction reflected a cautious market with controlled demand and balanced supply. As production activities gradually picked up towards the end of March several suppliers began adjusting price offers for the upcoming quarter in response to anticipated healthcare needs.
Europe
The Monosulfiram market in Europe maintained steady pricing throughout the first quarter of 2025. Market activity stayed within a consistent and predictable range, supported by stable demand from the pharmaceutical sector. Requirements for dermatological treatments and anti-parasitic medicines which is one of the primary uses for pharmaceutical-grade Monosulfiram in this region, continued at a regular pace and contributed to balanced market conditions.
Buyers showed a careful and planned procurement strategy throughout the quarter. Many companies focused on purchasing in smaller and routine volumes to ensure their inventory levels were balanced without risking overstock. This cautious buying behaviour was mainly due to moderate demand and the absence of any major seasonal spikes in medical requirements during the winter to early spring months.
Suppliers maintained a stable supply chain which was supported by smooth logistics and reliable product availability. The absence of any significant supply disruptions allowed the market to avoid sharp price fluctuations. Minor adjustments in offers were occasionally observed on a transactional basis. Both suppliers and buyers remained attentive to international pricing signals during the production and procurement cycles in the first quarter of 2025.
